StocktoriaBarinthus Biotherapeutics plc. BRNS
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-7.14
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $15.0M | $802,000 | $44.7M | $268,000 |
| Operating income | -$70.6M | -$68.0M | -$83.9M | -$4.0M | -$45.2M |
| Net income | -$66.4M | -$61.1M | -$73.3M | $5.3M | -$50.9M |
| Operating cash flow | -$48.0M | -$28.9M | -$50.9M | -$14.4M | -$32.6M |
| Free cash flow | -$48.0M | -$29.8M | -$56.3M | -$20.6M | -$33.7M |
| Total assets | $98.2M | $160.3M | $214.5M | $270.2M | $280.7M |
| Total liabilities | $23.9M | $30.2M | $27.5M | $27.0M | $28.2M |
| Shareholders' equity | $74.2M | $130.1M | $187.0M | $243.2M | $252.6M |
| Ratios | |||||
| Operating margin | — | -454.1% | -10463.1% | -9.0% | -16873.5% |
| Net margin | — | -408.0% | -9145.5% | 11.9% | -18979.5% |
| FCF margin | — | -199.3% | -7024.7% | -46.0% | -12585.4% |
| Return on assets | -67.7% | -38.1% | -34.2% | 2.0% | -18.1% |
| Return on equity | -89.5% | -46.9% | -39.2% | 2.2% | -20.1% |
| Current ratio | 7.77 | 8.03 | 12.45 | 17.40 | 20.32 |
| Revenue growth | -100.0% | 1766.5% | -98.2% | 16580.2% | -94.4% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 151,000 | $85,919 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.14 (distress)
- Working capital / assets 0.69
- Retained earnings / assets -3.098
- EBIT / assets -0.719
- Equity / liabilities 3.108
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001828185 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.